Cross Country buys privately held Akos for $14 mln

(Reuters) - Akos, which is a provider of drug safety, regulatory and
clinical trial services to pharmaceutical and biotechnology
companies, had revenue of $5.5 million for its fiscal year
ended Oct. 31.





Read more at Reuters.com Mergers News